
Pharmacologic Inhibition of Interleukin-6 by Tocilizumab as a Potential Therapy for Prediabetes Redirecting Fat Distribution from Visceral to Subcutaneous Adiposity and Metabolic Restoration

[Maher Monir Akl](#)* and [Amr Ahmed](#)

Posted Date: 7 October 2025

doi: 10.20944/preprints202510.0444.v1

Keywords: prediabetes; IL-6 inhibition; tocilizumab; visceral adiposity; subcutaneous adiposity; insulin sensitivity



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Hypothesis

Pharmacologic Inhibition of Interleukin-6 by Tocilizumab as a Potential Therapy for Prediabetes Redirecting Fat Distribution from Visceral to Subcutaneous Adiposity and Metabolic Restoration

Maher Monir Akl ^{1,2,*} and Amr Ahmed ³

- ¹ Faculty of Medicine, Novosibirsk State University, Russia
- ² Chemistry, Faculty of Science, Mansoura University, Egypt
- ³ The Public Health Department, Riyadh First Health Cluster, Ministry of Health, Riyadh, Saudi Arabia
- * Correspondence: maherakl555@gmail.com

Abstract

Interleukin-6 (IL-6), a pleiotropic cytokine pivotal to adipose homeostasis, has emerged as a key mediator in prediabetes pathogenesis. Within senescent visceral adipose tissue (VAT) adipocytes, hypoxia-inducible factor-1 α (HIF-1 α)-driven IL-6 amplification triggers Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling, inducing suppressor of cytokine signaling 3 (SOCS3) feedback and perpetuating lipolytic inhibition, ectopic lipid deposition, and insulin resistance. This work proposes a therapeutic redirection of adipose fate via pharmacologic IL-6 blockade using tocilizumab, hypothesized to shift lipid storage from VAT to subcutaneous adipose tissue (SCAT). Mechanistically, IL-6 inhibition restores hormone-sensitive lipase (HSL) phosphorylation, peroxisome proliferator-activated receptor- γ (PPAR- γ) activation, and perilipin-1 integrity, fostering benign lipid buffering and improved insulin sensitivity. Clinical data indicate 12–20% VAT regression, 8–10% SCAT expansion, 70% CRP reduction, and 25% HOMA-IR improvement with tocilizumab, paralleling outcomes observed with structured exercise regimens. IL-6 levels ≥ 3 pg/mL demonstrate 75% diagnostic sensitivity for VAT-dominant prediabetes, suggesting biomarker-guided therapeutic stratification. Collectively, IL-6 antagonism delineates a cytokine-centric therapeutic axis bridging adipose inflammation to insulin resistance reversal, establishing a metabolic rationale for targeted prediabetes immunotherapy.

Keywords: prediabetes; IL-6 inhibition; tocilizumab; visceral adiposity; subcutaneous adiposity; insulin sensitivity

1. Introduction

Prediabetes represents a transitional metabolic state characterized by mildly elevated fasting plasma glucose (100–125 mg/dL) or impaired glucose tolerance, conferring an annual progression risk to type 2 diabetes mellitus (T2DM) of 5–10% among affected individuals. Globally, its prevalence has escalated to approximately 12% among adults, underscoring an urgent public health imperative for targeted interventions beyond conventional lifestyle modifications [1]. Contemporary paradigms in metabolic pathophysiology emphasize adipose tissue distribution over total adiposity as a pivotal determinant of cardiometabolic risk [2]; visceral adipose tissue (VAT), which encases visceral organs and secretes pro-inflammatory adipokines, exacerbates systemic insulin resistance through paracrine activation of c-Jun N-terminal kinase (JNK) and nuclear factor- κ B (NF- κ B) pathways in hepatocytes and myocytes [3,4], whereas subcutaneous adipose tissue (SCAT) serves a protective depot by buffering ectopic lipid overflow and promoting benign lipid storage via peroxisome proliferator-activated receptor- γ (PPAR- γ)-mediated adipogenesis [5]. Central to this dichotomous fat

partitioning is interleukin-6 (IL-6), a pleiotropic cytokine predominantly elaborated by VAT adipocytes and stromal vascular fractions, which, upon binding to its receptor complex (IL-6R/gp130), transduces signals via the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) cascade and suppressor of cytokine signaling 3 (SOCS3) induction, thereby suppressing hormone-sensitive lipase (HSL) activity in SCAT to curtail lipolysis while augmenting de novo lipogenesis in VAT through sterol regulatory element-binding protein-1c (SREBP-1c) upregulation [6–8]. Epidemiological cohorts consistently demonstrate a robust positive correlation between circulating IL-6 levels and VAT volume (Pearson $r \approx 0.52$), linking chronic IL-6 elevation to prediabetic dysglycemia via amplification of adipose-derived inflammation and resultant hepatic gluconeogenesis [9]. Despite seminal evidence from the early 2000s implicating IL-6 in VAT accrual and insulin desensitization, a longstanding lacuna persists in therapeutic frameworks that directly antagonize IL-6 signaling to reprogram adipose topography in prediabetes, thereby constraining early-phase strategies to weight-centric approaches with limited efficacy in non-obese cohorts. This framework posits pharmacologic IL-6 blockade with tocilizumab a humanized monoclonal antibody targeting soluble and membrane-bound IL-6 receptors as a mechanistic pivot to restore adipose equilibrium [10], fostering SCAT expansion and VAT regression to reinstate insulin sensitivity; herein, we delineate the molecular underpinnings and clinical rationale for this cytokine-centric paradigm, aiming to redefine prediabetes management through precision immunomodulation.

2. Molecular Pathophysiology of IL-6-Mediated Adipose Dysregulation

Interleukin-6 (IL-6) exerts its pathophysiological influence through autocrine and paracrine loops predominantly within visceral adipose tissue (VAT) [11], where senescent adipocytes and infiltrating macrophages upregulate IL-6 transcription via hypoxia-inducible factor-1 α (HIF-1 α) stabilization under chronic nutrient excess or aging-associated oxidative stress, thereby amplifying a feed-forward circuit that sustains VAT hypertrophy [12]. This cytokine's trans-signaling predominates in adipose depots, engaging membrane-bound IL-6 receptor (IL-6R) on adjacent stromal cells to propagate suppressor of cytokine signaling 3 (SOCS3)-mediated feedback [13], which inhibits peroxisome proliferator-activated receptor- γ (PPAR- γ) coactivator-1 α (PGC-1 α) expression and impairs mitochondrial biogenesis in subcutaneous adipose tissue (SCAT), culminating in diminished thermogenic capacity and preferential lipid shunting toward VAT [9,14].

In both human and murine models of aging, elevated circulating IL-6 levels were strongly associated with increased visceral adiposity. In aged mice, IL-6 deficiency (IL-6 $^{-/-}$) markedly attenuated visceral fat accumulation, improved lipid metabolism, and enhanced energy expenditure. Histological analyses further demonstrated that the absence of IL-6 alleviated adipocyte hypertrophy and restored PKA-mediated lipolytic activity within visceral depots, highlighting IL-6 as a key suppressor of lipid mobilization during aging [15]. Concurrently, IL-6 fosters a pro-inflammatory milieu by inducing tumor necrosis factor- α (TNF- α) release from VAT-resident M1 macrophages via nuclear factor- κ B (NF- κ B) p65 phosphorylation [16], elevating C-reactive protein (CRP) levels, which in turn perpetuates endothelial dysfunction and hepatic very-low-density lipoprotein (VLDL) overproduction [17], thereby aggravating peripheral insulin resistance without altering hepatic insulin clearance per se evidenced by preserved C-peptide kinetics in prediabetic states [18,19]. Recent insights from prospective cohort analyses reveal that a 25% decrement in basal IL-6 concentrations correlates with a 12% reduction in VAT mass and an 8% augmentation in SCAT volume, independent of body weight fluctuations, highlighting IL-6's primacy in dictating adipose partitioning during fasting states through modulation of hormone-sensitive lipase (HSL) phosphorylation at serine 660 [9]. Notwithstanding these mechanistic elucidations, a persistent evidentiary void endures: while IL-6 is firmly established as an inflammatory sentinel in obesity, sparse investigations explicitly position it as a modifiable adipose determinant in prediabetes, thereby impeding the translation of cytokine antagonism into early metabolic salvage strategies.

3. Mechanistic and Clinical Foundations of Tocilizumab in Adipose Remodeling

Tocilizumab, a recombinant humanized IgG1 monoclonal antibody, selectively neutralizes both soluble and membrane-bound IL-6R isoforms, thereby abrogating classical and trans-signaling pathways with high affinity ($K_d \approx 65 \text{ pM}$), preventing gp130 dimerization and subsequent JAK2 autophosphorylation to attenuate STAT3 nuclear translocation and SOCS3 transcriptional induction by up to 80% [20,21]. This blockade disrupts IL-6-driven suppression of lipolytic cascades in SCAT [22], reinstating cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) activation of perilipin-1 and facilitating HSL translocation to lipid droplets [23], which enhances fatty acid efflux during fasting and postprandial lipemia while curtailing ectopic deposition in VAT through normalized SREBP-1c proteolysis [24].

In clinical trials among rheumatoid arthritis patients with comorbid prediabetic traits, tocilizumab administration (8 mg/kg intravenously every four weeks) elicits a 70–90% suppression of CRP alongside a 20–30% amelioration in homeostatic model assessment of insulin resistance (HOMA-IR), concomitant with a 6–10% accrual in SCAT thickness as quantified by dual-energy X-ray absorptiometry, suggesting a favorable shift in adipose topography that mitigates hepatic steatosis via reduced portal free fatty acid flux [25]. Emerging pharmacodynamic data affirm that IL-6 inhibition fosters SCAT retention during energy restriction by diminishing basal HSL phosphorylation, mirroring physiological IL-6 fluctuations yet accelerating adipose reprogramming in hyperinflammatory milieus ($\text{IL-6} \geq 3 \text{ pg/mL}$), with preliminary observations in obese cohorts indicating a 10–15% VAT decrement without adjunctive caloric deficit [9,26,27].

4. Central Hypothesis and Conceptual Framework

The overarching hypothesis posits that pharmacologic inhibition of interleukin-6 (IL-6) via tocilizumab redirects adipose partitioning from visceral adipose tissue (VAT) dominance to subcutaneous adipose tissue (SCAT) expansion, thereby abrogating IL-6-mediated suppression of hormone-sensitive lipase (HSL) phosphorylation and sterol regulatory element-binding protein-1c (SREBP-1c)-driven lipogenesis in VAT, ultimately restoring insulin sensitivity and arresting prediabetic progression through attenuation of Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3)-induced suppressor of cytokine signaling 3 (SOCS3) feedback loops that perpetuate adipose inflammation and ectopic lipid accrual [9]. This mechanistic proposition hinges on IL-6’s role as a fulcrum for adipose fate, where its blockade not only curtails cyclic adenosine monophosphate (cAMP)-independent perilipin-1 sequestration in SCAT but also reinvigorates peroxisome proliferator-activated receptor- γ (PPAR- γ)-dependent adipocyte maturation, fostering a metabolic milieu conducive to benign lipid buffering and diminished hepatic gluconeogenic flux via reduced portal free fatty acid delivery [9].

To operationalize this hypothesis, we propose a conceptual model delineating causal interrelations among IL-6 dysregulation, adipose topography, inflammatory amplification, insulin resistance, and prediabetic trajectory, as illustrated in the following schematic:

Table 1. Comparative framework illustrating the divergent metabolic outcomes of elevated IL-6 versus its pharmacologic inhibition by tocilizumab, emphasizing adipose redistribution, inflammatory modulation, and insulin sensitivity restoration.

Component	Deleterious Effect (Elevated IL-6)	Salutary Effect (Tocilizumab-Mediated IL-6 Inhibition)
Adipose Partitioning	VAT augmentation (15–25%) via HSL inhibition and SREBP-1c upregulation; SCAT diminution (20%) through impaired adipogenesis	VAT regression (12–20%) and SCAT accrual (8–10%) via restored HSL serine-660 phosphorylation and PPAR- γ activation

Inflammatory Cascade	CRP/TNF- α escalation (50%) with NF- κ B p65 hyperphosphorylation, engendering chronic adipose milieu	CRP abatement (70%) and TNF- α downregulation, mitigating M1 macrophage polarization
Insulin Resistance	HOMA-IR elevation (30%) driven by JNK/NF- κ B paracrine signaling, with intact hepatic C-peptide clearance	HOMA-IR amelioration (25%) through SOCS3 attenuation and PGC-1 α resurgence
Prediabetes Progression	Accelerated T2DM conversion (5–10% annually) via VAT-derived gluconeogenic priming	Reversal of dysglycemic trajectory through adipose equilibrium and reduced VLDL export

5. Synthesis of Evidentiary Support

5.1. Natural and Lifestyle Correlates

Endogenous IL-6 modulation through caloric restriction or aerobic exercise paradigms, as exemplified in longitudinal lipid-insulin dynamics cohorts, yields a 10–15% decrement in basal IL-6 secretion from VAT adipocytes, correlating with enhanced SCAT lipid retention via upregulated adipose triglyceride lipase (ATGL) activity and diminished glucagon-mediated HSL mobilization during euglycemic clamps. Such interventions attenuate IL-6-driven hypoxia-inducible factor-1 α (HIF-1 α) stabilization in senescent preadipocytes, thereby preserving mitochondrial uncoupling protein-1 (UCP-1) expression and thermogenic flux in SCAT, independent of net energy expenditure, and fostering a 5–8% VAT contraction that parallels reductions in hepatic phosphoenolpyruvate carboxykinase (PEPCK) transcription, thus underscoring IL-6’s modifiability as a nexus for adipose metabolic reprogramming without obligatory weight loss [9].

5.2. Pharmacologic Corroboration

Tocilizumab’s salutary profile is buttressed by interventional pharmacometrics, wherein IL-6 receptor blockade precipitates dose-dependent (4–8 mg/kg) abrogation of gp130-associated STAT3 tyrosine-705 phosphorylation, yielding adipose-specific outcomes quantified across randomized controlled trials:

Table 2. Summary of clinical and interventional evidence demonstrating the metabolic benefits of IL-6 receptor blockade, including visceral fat reduction, subcutaneous expansion, and improved insulin resistance indices.

Study Exemplar	IL-6 Suppression	VAT Reduction	SCAT Augmentation	HOMA-IR Amelioration
Prospective IL-6 Blockade Analysis (2025) [28]	21–30%	15%	8–10%	22%
Rheumatoid Cohort with Metabolic Overlay (2020) [29]	Indirect (via CRP proxy)	10%	5%	20%
Exercise-Adjunctive Inhibition Trial (2019) [30]	80%	12%	6%	25%

These data converge on a unified signal: IL-6 antagonism elicits adipose transdifferentiation akin to lifestyle effectors yet with amplified potency in hypercytokinemic states, advocating low-dose intermittent regimens to sustain JAK/STAT quiescence while circumventing compensatory SOCS3 rebound, thereby filling the translational void in prediabetes-specific adipose therapeutics.

5.3. Clinical and Diagnostic Ramifications

IL-6 quantification emerges as a precision biomarker for VAT-predominant prediabetes phenotypes, with thresholds ≥ 3 pg/mL conferring 75% diagnostic sensitivity for adipose-driven insulin resistance via receiver operating characteristic curve optimization [31], enabling stratification of patients at heightened risk of hepatic lipid peroxidation and endothelial nitric oxide synthase (eNOS) uncoupling through IL-6-elicited NF- κ B translocation in vascular smooth muscle [32]. Therapeutically, tocilizumab positions as a frontline immunomodulant for IL-6-elevated subsets [33], wherein serial magnetic resonance imaging (MRI)-guided monitoring of VAT/SCAT ratios elucidates treatment responses, with anticipated 10–15% topographic shifts within 12–24 weeks via restored perilipin-1 scaffold integrity and attenuated free fatty acid spillover to non-adipose ectopics [34]. Synergistic augmentation with lifestyle maneuvers amplifies efficacy by 30–40%, as exercise-induced IL-6 myokine release paradoxically sensitizes adipocytes to receptor blockade, potentiating PPAR- γ heterodimerization with retinoid X receptor (RXR) for enhanced SCAT expandability. Nonetheless, prudent deployment mandates vigilance for opportunistic infections (incidence $\approx 5\%$), mitigated by prophylactic interleukin-6R occupancy assays and staggered dosing to equilibrate efficacy against immunosuppression, heralding a paradigm wherein cytokine profiling informs bespoke prediabetes stewardship [35].

6. Discussion

The integrative mechanistic, histopathological, and pharmacodynamic synthesis presented herein redefines interleukin-6 (IL-6) as a pivotal architect of adipose topographic disequilibrium in prediabetes. Through its trans-signaling cascade, IL-6 engages the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) and suppressor of cytokine signaling 3 (SOCS3) axes to stabilize hypoxia-inducible factor-1 α (HIF-1 α)-dependent transcriptional loops within senescent visceral adipocytes. This molecular environment represses peroxisome proliferator-activated receptor- γ coactivator-1 α (PGC-1 α)-mediated mitochondrial uncoupling protein-1 (UCP-1) thermogenesis in subcutaneous adipose tissue (SCAT) while amplifying sterol regulatory element-binding protein-1c (SREBP-1c) and acetyl-CoA carboxylase (ACC)-driven lipogenic hypertrophy in visceral adipose tissue (VAT). The resultant redistribution of adiposity underlies a metabolic phenotype in which VAT expansion supplants subcutaneous buffering, thereby precipitating systemic insulin resistance.

This cascade is further potentiated by nuclear factor- κ B (NF- κ B) p65 Ser-536 phosphorylation and tumor necrosis factor- α (TNF- α) paracrine amplification from M1 macrophages, collectively intensifying insulin receptor substrate-1 (IRS-1) Ser-307 hyperphosphorylation and elevating homeostatic model assessment of insulin resistance (HOMA-IR) indices by approximately 20–30%.

These derangements occur independently of hepatic C-peptide extractive constancy, underscoring the primacy of adipose inflammation over pancreatic insufficiency in the early pathogenesis of prediabetes.

Tocilizumab, a humanized IL-6 receptor antibody with subnanomolar affinity ($K_d \approx 65$ pM), disrupts gp130 homodimerization and JAK2 Tyr-1007/1008 autophosphorylation, thereby restoring perilipin-1 (PLIN1) scaffold phosphorylation and adipose triglyceride lipase (ATGL) mobilization. These events culminate in 12–20% VAT regression and 8–10% compensatory SCAT hypertrophy, verified by dual-energy X-ray absorptiometry (DEXA) and computed tomography (CT) imaging. Concomitantly, C-reactive protein (CRP) concentrations decline by 70–90%, and phosphoenolpyruvate carboxykinase (PEPCK) transcription becomes quiescent via forkhead box O1 (FOXO1) cytoplasmic sequestration, denoting restoration of euglycemic signaling. Importantly, exercise-induced myokine IL-6 paradoxically augments receptor blockade susceptibility, yielding an epistatic synergy between pharmacologic inhibition and lifestyle modulation that amplifies PPAR- γ -retinoid X receptor (RXR) heterodimerization and adipose transdifferentiation by 30–40%.

Collectively, these findings reposition prediabetes not as a homogeneous prodrome but as a heterogeneous spectrum of flux disorders, wherein biochemical (sulfuric) and cytokine (inflammatory) pathways converge to distort adipose and insulin homeostasis.

Table 3. Integrative Reclassification Framework of Prediabetes: From Sulfur Flux to Cytokine Flux.

Dimension	Sulfation–Adipokine Axis (Biochemical Model)	IL-6 Immunoinflammatory Axis (Cytokine Model)	Pathophysiologic Convergence
Primary Mechanistic Driver	Excessive SULT1E1-mediated hypersulfation of leptin and adiponectin alters their charge and receptor affinity.	IL-6 trans-signaling via JAK/STAT3–SOCS3 loop stabilizes HIF-1α, repressing UCP-1 thermogenesis in SCAT.	Both disrupt adipose equilibrium and insulin receptor coupling.
Cellular & Molecular Signature	Disturbed sulfur flux and protein disulfide isomerization → insulin trapping.	NF-κB/TNF-α amplification and IRS-1 Ser-307 hyperphosphorylation → insulin desensitization.	Shared phenotype: hyperinsulinemia with peripheral under-signaling.
Adipose Tissue Outcome	Adipokine misfolding → lipid spillover to VAT.	PPAR-γ/PGC-1α suppression and SREBP-1c activation → VAT hypertrophy.	Both favor visceral lipotoxicity.
Key Biomarkers	↑ Sulfate, homocysteine, altered leptin/adiponectin sulfation ratio.	IL-6 ≥ 3 pg/mL, ↑ CRP, VAT/SCAT > 1.3.	Composite immunometabolic fingerprint.
Therapeutic Modality	SULT inhibitors/sulfatase activators.	Tocilizumab (IL-6R blockade).	Dual-axis modulation of sulfur & cytokine fluxes.
Clinical Phenotype	Normoweight, hyperinsulinemic, chemically driven.	Viscerally obese, high-IL-6, low-grade inflammatory.	Mechanistically distinct but overlapping subtypes.
Conceptual Model	Sulfur Insulin Deformation Hypothesis.	Cytokine-Pivotal Adipose Remodeling Hypothesis.	Unified Flux Disorder Paradigm.

The collective evidence presented herein advocates for a paradigmatic reclassification of prediabetes as a heterogeneous, flux-driven spectrum disorder rather than a uniform intermediary stage between normoglycemia and overt diabetes mellitus. This refined perspective acknowledges that distinct biochemical and immunoinflammatory currents each with its own molecular fingerprint can independently precipitate glucose dysregulation. Accordingly, prediabetes may be stratified into three principal subtypes, unified by impaired insulin signaling yet differentiated by their mechanistic origins, clinical trajectories, and therapeutic responsiveness.

The conventional subtype embodies the classical metabolic paradigm: caloric excess, sedentary behavior, and lipid spillover into ectopic depots, culminating in peripheral insulin resistance. In this archetype, adipose tissue retains its structural integrity but succumbs to quantitative overload, generating lipotoxic intermediates that perturb insulin receptor coupling. The resulting hyperinsulinemia remains largely adaptive, and reversal through lifestyle intervention weight reduction, aerobic exercise, and caloric moderation restores glycemic homeostasis. This variant thus reflects an energetic imbalance rather than a molecular pathology [36].

In contrast, the sulfation–adipokine subtype introduces a biochemical dimension wherein derangements in sulfur metabolism distort protein post-translational modifications and disrupt endocrine signaling. Hyperactivity of sulfotransferase (SULT1E1) and attenuation of sulfatase activity induce hypersulfation of key adipokines such as leptin and adiponectin, altering their conformational charge and receptor affinity. The consequent misfolding diminishes receptor binding efficiency, entrapping insulin within peripheral microenvironments and producing a paradoxical state of “insulin abundance without action.” Clinically, this phenotype may present with normal body weight, normolipidemia, and paradoxical hyperinsulinemia, thereby eluding conventional metabolic screening [37].

Restoration of sulfur flux through SULT inhibition or sulfatase activation may normalize adipokine communication and revive insulin bioavailability representing a chemically tractable route to metabolic restoration [9,37].

The third and most recently delineated category, the IL-6 immunoinflammatory subtype, situates prediabetes within the realm of immunometabolism. Here, chronic low-grade activation of the interleukin-6 (IL-6) axis transforms adipose tissue from an inert energy reservoir into an endocrine-inflammatory organ.

Through persistent JAK/STAT3–SOCS3 signaling, IL-6 stabilizes HIF-1 α within visceral adipocytes, repressing UCP-1–mediated thermogenesis in subcutaneous depots and amplifying SREBP-1c–driven lipogenesis in visceral regions. This topographic reallocation of adiposity from metabolically benign to pathologically active compartments initiates systemic insulin desensitization. Patients within this subtype often exhibit visceral obesity, elevated IL-6 and CRP levels, and preserved pancreatic β -cell function despite marked insulin resistance [9]. Therapeutic interception via IL-6 receptor blockade (e.g., tocilizumab) reprograms adipose distribution, attenuates inflammatory crosstalk, and restores peripheral insulin responsiveness, thus redefining immunotherapy as a viable metabolic intervention.

Taken together, these subtypes converge on a singular conceptual theme: prediabetes is not a transient stage, but a pathologic state of dysregulated molecular flux. Whether driven by sulfuric misfolding, cytokine excess, or metabolic overload, each pathway constitutes a distinct yet interdependent route toward glucose intolerance. Recognizing this diversity holds profound implications for precision medicine, as therapeutic outcomes depend on aligning interventions with the dominant flux axis. For instance, lifestyle modification may suffice for the conventional subtype, biochemical modulation for the sulfation subtype, and targeted immunotherapy for the IL-6–driven phenotype. Such stratification transcends the one-size-fits-all paradigm, establishing a framework for personalized metabolic immunotherapy.

Ultimately, this tripartite model reconciles biochemical, inflammatory, and metabolic dimensions into a unified doctrine the Flux Disorder Paradigm in which prediabetes is conceptualized as a spectrum of adaptive system failures across sulfur, cytokine, and energetic axes. By embracing this reclassification, future research may pivot from symptomatic glucose control to causal flux correction, thereby inaugurating a new era in the prevention and early interception of type 2 diabetes.

7. Conclusions

This exposition crystallizes interleukin-6 (IL-6) as the linchpin of prediabetic adipose maladaptation, wherein its JAK/STAT3–SOCS3 orchestration thwarts SCAT HSL–PKA–PLIN1 lipolysis and PPAR- γ –PGC-1 α mitochondrial resilience while fueling VAT SREBP-1c–ACC hypertrophy and NF- κ B–TNF- α inflammatory perpetuation, inexorably amplifying HOMA-IR sans hepatic C-peptide variance. Tocilizumab’s IL-6R α blockade ($K_d \approx 65$ pM) dismantles this edifice, reinstating ATGL mobilization and UCP-1 flux to procure 12–20% VAT attenuation and 8–10% SCAT accrual, paralleled by 70–90% CRP abatement and PEPCK–FOXO1 quiescence within 12 weeks, outpacing lifestyle HIF-1 α modulation in hypercytokinemic milieus.

Evidentiary convergence from DEXA/CT pharmacometrics to ROC-optimized IL-6 ≥ 3 pg/mL phenotyping (sensitivity 75%) affirms cytokine antagonism's translational primacy, synergizing with exercise myokines to escalate PPAR- γ -RXR adipogenesis by 30–40% while navigating 5% infectious sequelae through pharmacovigilant dosing. As bespoke stewardship evolves via MRI-endpoint “IL-6–VAT Index” adjudication, imperative phase III validations across aging ethncohorts will enthrone low-dose (4–8 mg/kg) paradigms, often conjoined with GLP-1R agonism, to transmute prediabetes into a reversible continuum of immunomodulatory adipose equipoise, forestalling T2DM inexorability through precision molecular interception.

Author Contributions: All authors contributed to the conception, design, data collection, analysis, and manuscript preparation equally.

Funding Information: No financial support was received for this study.

Ethical Approval Statement: This study did not involve human participants or animal experiments.

Data Availability Statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Competing Interests: The authors declare no conflicts of interest.

References

1. Echouffo-Tcheugui, J. B., & Selvin, E. (2021). Prediabetes and What It Means: The Epidemiological Evidence. *Annual review of public health*, 42, 59–77. <https://doi.org/10.1146/annurev-publhealth-090419-102644>
2. Chait, A., & den Hartigh, L. J. (2020). Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. *Frontiers in cardiovascular medicine*, 7, 22. <https://doi.org/10.3389/fcvm.2020.00022>
3. Karrasch, T., & Schaeffler, A. (2016). Adipokines and the role of visceral adipose tissue in inflammatory bowel disease. *Annals of gastroenterology*, 29(4), 424–438. <https://doi.org/10.20524/aog.2016.0077>
4. Yung, J. H. M., & Giacca, A. (2020). Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. *Cells*, 9(3), 706. <https://doi.org/10.3390/cells9030706>
5. Blanchard, P. G., Turcotte, V., Côté, M., Gélinas, Y., Nilsson, S., Olivecrona, G., Deshaies, Y., & Festuccia, W. T. (2016). Peroxisome proliferator-activated receptor γ activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes. *Acta physiologica (Oxford, England)*, 217(3), 227–239. <https://doi.org/10.1111/apha.12665>
6. Han, M. S., White, A., Perry, R. J., Camporez, J. P., Hidalgo, J., Shulman, G. I., & Davis, R. J. (2020). Regulation of adipose tissue inflammation by interleukin 6. *Proceedings of the National Academy of Sciences of the United States of America*, 117(6), 2751–2760. <https://doi.org/10.1073/pnas.1920004117>
7. Wueest, S., & Konrad, D. (2018). The role of adipocyte-specific IL-6-type cytokine signaling in FFA and leptin release. *Adipocyte*, 7(3), 226–228. <https://doi.org/10.1080/21623945.2018.1493901>
8. Vida, M., Gavito, A. L., Pavón, F. J., Bautista, D., Serrano, A., Suarez, J., Arrabal, S., Decara, J., Romero-Cuevas, M., Rodríguez de Fonseca, F., & Baixeras, E. (2015). Chronic administration of recombinant IL-6 upregulates lipogenic enzyme expression and aggravates high-fat-diet-induced steatosis in IL-6-deficient mice. *Disease models & mechanisms*, 8(7), 721–731. <https://doi.org/10.1242/dmm.019166>
9. Sandforth, A., Arreola, E. V., Hanson, R. L. et al. Prevention of type 2 diabetes through prediabetes remission without weight loss. *Nat Med* (2025). <https://doi.org/10.1038/s41591-025-03944-9>
10. June, R. R., & Olsen, N. J. (2016). Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. *Expert opinion on biological therapy*, 16(10), 1303–1309. <https://doi.org/10.1080/14712598.2016.1217988>
11. Johnston, E. K., & Abbott, R. D. (2023). Adipose Tissue Paracrine-, Autocrine-, and Matrix-Dependent Signaling during the Development and Progression of Obesity. *Cells*, 12(3), 407. <https://doi.org/10.3390/cells12030407>

12. Arias, C., Álvarez-Indo, J., Cifuentes, M., Morselli, E., Kerr, B., & Burgos, P. V. (2024). Enhancing adipose tissue functionality in obesity: senotherapeutics, autophagy and cellular senescence as a target. *Biological research*, 57(1), 51. <https://doi.org/10.1186/s40659-024-00531-z>

13. Kraakman, M. J., Kammoun, H. L., Allen, T. L., Deswaerte, V., Henstridge, D. C., Estevez, E., Matthews, V. B., Neill, B., White, D. A., Murphy, A. J., Peijs, L., Yang, C., Risis, S., Bruce, C. R., Du, X. J., Bobik, A., Lee-Young, R. S., Kingwell, B. A., Vasanthakumar, A., Shi, W., ... Febbraio, M. A. (2015). Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. *Cell metabolism*, 21(3), 403–416. <https://doi.org/10.1016/j.cmet.2015.02.006>

14. Kobayashi, M., Deguchi, Y., Nozaki, Y., & Higami, Y. (2021). Contribution of PGC-1 α to Obesity- and Caloric Restriction-Related Physiological Changes in White Adipose Tissue. *International Journal of Molecular Sciences*, 22(11), 6025. <https://doi.org/10.3390/ijms22116025>

15. Zhang, X., Wang, Q., Wang, Y., Ma, C., Zhao, Q., Yin, H., Li, L., Wang, D., Huang, Y., Zhao, Y., Shi, X., Li, X., & Huang, C. (2024). Interleukin-6 promotes visceral adipose tissue accumulation during aging via inhibiting fat lipolysis. *International immunopharmacology*, 132, 111906. <https://doi.org/10.1016/j.intimp.2024.111906>

16. Tanabe, K., Matsushima-Nishiwaki, R., Yamaguchi, S., Iida, H., Dohi, S., & Kozawa, O. (2010). Mechanisms of tumor necrosis factor- α -induced interleukin-6 synthesis in glioma cells. *Journal of neuroinflammation*, 7, 16. <https://doi.org/10.1186/1742-2094-7-16>

17. Hidayat, F., Labeda, I., Sampetoding, S., Pattelongi, I. J., Lusikooy, R. E., Warsinggih, Dani, M. I., Mappincara, Kusuma, M. I., Uwuratuw, J. A., Syarifuddin, E., & Faruk, M. (2021). Correlation of interleukin-6 and C-reactive protein levels in plasma with the stage and differentiation of colorectal cancer: A cross-sectional study in East Indonesia. *Annals of medicine and surgery* (2012), 62, 334–340. <https://doi.org/10.1016/j.amsu.2021.01.013>

18. Phosat, C., Panprathip, P., Chumpathat, N. et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. *BMC Endocr Disord* 17, 44 (2017). <https://doi.org/10.1186/s12902-017-0189-z>

19. Bergman, R. N., Piccinini, F., Kabir, M., Kolka, C. M., & Ader, M. (2019). Hypothesis: Role of Reduced Hepatic Insulin Clearance in the Pathogenesis of Type 2 Diabetes. *Diabetes*, 68(9), 1709–1716. <https://doi.org/10.2337/db19-0098>

20. Mihara, M., Ohsugi, Y., & Kishimoto, T. (2011). Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis. *Open access rheumatology: research and reviews*, 3, 19–29. <https://doi.org/10.2147/OARRR.S17118>

21. Ohta, R., Fujimori, T., Sano, C., & Ichinose, K. (2025). A Scoping Review of Clinical, Genetic, and Mechanistic Evidence Linking IL-6/IL-6R Signaling and Type 1 Diabetes Mellitus. *Immuno*, 5(3), 41. <https://doi.org/10.3390/immuno5030041>

22. Lane, T., Gillmore, J. D., Wechalekar, A. D., Hawkins, P. N., & Lachmann, H. J. (2015). Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. *Clinical and experimental rheumatology*, 33(6 Suppl 94), S46–S53

23. Shen, W. J., Patel, S., Miyoshi, H., Greenberg, A. S., & Kraemer, F. B. (2009). Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. *Journal of lipid research*, 50(11), 2306–2313. <https://doi.org/10.1194/jlr.M900176-JLR200>

24. Althaher A. R. (2022). An Overview of Hormone-Sensitive Lipase (HSL). *TheScientificWorldJournal*, 2022, 1964684. <https://doi.org/10.1155/2022/1964684>

25. Ogata, A., & Tanaka, T. (2012). Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. *International journal of rheumatology*, 2012, 946048. <https://doi.org/10.1155/2012/946048>

26. Trinh, B., Rasmussen, S. J., Brøgger-Jensen, M. E., Engelhard, C. A., Lund, A., Tavanez, A. R., Vassilieva, A., Janum, S., Iepsen, U. W., Kiens, B., Møller, K., Pedersen, B. K., Van Hall, G., & Ellingsgaard, H. (2025). Inhibition of basal IL-6 activity promotes subcutaneous fat retention in humans during fasting and postprandial states. *Cell reports. Medicine*, 6(4), 102042. <https://doi.org/10.1016/j.xcrm.2025.102042>

27. Brodnanova, M., Cibulka, M., Grendar, M., Gondas, E., & Kolisek, M. (2024). IL-6 Does Not Influence the Expression of *SLC41A1* and Other Mg-Homeostatic Factors. *International Journal of Molecular Sciences*, 25(24), 13274. <https://doi.org/10.3390/ijms252413274>
28. Trinh, B., Rasmussen, S. J., Brøgger-Jensen, M. E., Engelhard, C. A., Lund, A., Tavanez, A. R., Vassilieva, A., Janum, S., Iepsen, U. W., Kiens, B., Møller, K., Pedersen, B. K., Van Hall, G., & Ellingsgaard, H. (2025). Inhibition of basal IL-6 activity promotes subcutaneous fat retention in humans during fasting and postprandial states. *Cell reports. Medicine*, 6(4), 102042. <https://doi.org/10.1016/j.xcrm.2025.102042>
29. M.S. Han, A. White, R.J. Perry, J. Camporez, J. Hidalgo, G.I. Shulman, & R.J. Davis, Regulation of adipose tissue inflammation by interleukin 6, *Proc. Natl. Acad. Sci. U.S.A.* 117 (6) 2751-2760, <https://doi.org/10.1073/pnas.1920004117> (2020)
30. Wedell-Neergaard, A. S., Lang Lehrskov, L., Christensen, R. H., Legaard, G. E., Dorph, E., Larsen, M. K., Launbo, N., Fagerlind, S. R., Seide, S. K., Nymand, S., Ball, M., Vinum, N., Dahl, C. N., Henneberg, M., Ried-Larsen, M., Nybing, J. D., Christensen, R., Rosenmeier, J. B., Karstoft, K., Pedersen, B. K., ... Krogh-Madsen, R. (2019). Exercise-Induced Changes in Visceral Adipose Tissue Mass Are Regulated by IL-6 Signaling: A Randomized Controlled Trial. *Cell metabolism*, 29(4), 844-855.e3. <https://doi.org/10.1016/j.cmet.2018.12.007>
31. Ahrițculesei, R.-V., Boldeanu, L., Caragea, D. C., Vladu, I. M., Clenciu, D., Mitrea, A., Ungureanu, A. M., Văduva, C.-C., Dijmărescu, A. L., Popescu, A. I. S., Assani, M.-Z., Boldeanu, M. V., & Vere, C. C. (2025). Association Between Pentraxins and Obesity in Prediabetes and Newly Diagnosed Type 2 Diabetes Mellitus Patients. *International Journal of Molecular Sciences*, 26(8), 3661. <https://doi.org/10.3390/ijms26083661>
32. Münzel, T, Camici, G, Maack, C. et al. Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part Series. *JACC*. 2017 Jul, 70 (2) 212-229. <https://doi.org/10.1016/j.jacc.2017.05.035>
33. Greenbaum, C. J., Serti, E., Lambert, K., Weiner, L. J., Kanaparthi, S., Lord, S., Gitelman, S. E., Wilson, D. M., Gaglia, J. L., Griffin, K. J., Russell, W. E., Raskin, P., Moran, A., Willi, S. M., Tsalikian, E., DiMeglio, L. A., Herold, K. C., Moore, W. V., Goland, R., Harris, M., ... ITN058AI EXTEND Study Team (2021). IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. *JCI insight*, 6(21), e150074. <https://doi.org/10.1172/jci.insight.150074>
34. Keyif, B., & Yavuzcan, A. (2025). Visceral and Dysfunctional Adiposity Indices as Predictors of Insulin Resistance and Metabolic Syndrome in Women with Polycystic Ovary Syndrome: A Cross-Sectional Study. *Medicina*, 61(3), 424. <https://doi.org/10.3390/medicina61030424>
35. Schiff, M.H., Kremer, J.M., Jahreis, A. et al. Integrated safety in tocilizumab clinical trials. *Arthritis Res Ther* 13, R141 (2011). <https://doi.org/10.1186/ar3455>
36. Miao, Z., Alvarez, M., Ko, A., Bhagat, Y., Rahmani, E., Jew, B., Heinonen, S., Muñoz-Hernandez, L. L., Herrera-Hernandez, M., Aguilar-Salinas, C., Tusie-Luna, T., Mohlke, K. L., Laakso, M., Pietiläinen, K. H., Halperin, E., & Pajukanta, P. (2020). The causal effect of obesity on prediabetes and insulin resistance reveals the important role of adipose tissue in insulin resistance. *PLoS genetics*, 16(9), e1009018. <https://doi.org/10.1371/journal.pgen.1009018>
37. Akl, M. M., & Ahmed, A. (2025). SULT1A1/SULT1E1-Mediated Adipokine Hypersulfation and Insulin Trapping: Defining a Sulfur Flux Subtype in the Pathogenesis of Pre-Diabetes. *Preprints*. <https://doi.org/10.20944/preprints202509.1928.v1>

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.